Systematic Evaluation of Antiviral Medication in Schizophrenia - Full Text View

Sponsors and Collaborators:	University of Pittsburgh Stanley Medical Research Institute Wayne State University
Information provided by:	University of Pittsburgh
ClinicalTrials.gov Identifier:	NCT00514449

Purpose

The purpose of this study is to examine whether antiviral medication will help improve psychotic symptoms and cognition in individuals early in the course of schizophrenia or schizoaffective disorder who are exposed to herpes simplex virus, type 1 (HSV 1), a virus that causes commonly occurring and recurrent cold sores.

Condition	Intervention	Phase
Schizophrenia Schizoaffective Disorder	Drug: Valacyclovir + Antipsychotic Drug: Placebo + Antipsychotic	Phase II

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Efficacy Study
Official Title:	A Randomized Double-Blind Controlled Trial of Valacyclovir Add-on Treatment of HSV Positive Early Course Schizophrenia Patients

Resource links provided by NLM:

MedlinePlus related topics: Schizophrenia

Drug Information available for: Valaciclovir Valacyclovir hydrochloride

U.S. FDA Resources

Further study details as provided by University of Pittsburgh:

Primary Outcome Measures:

PANSS Positive and Negative Syndrome Scale for schizophrenia [ Time Frame: Baseline, Weeks 2, 4, 6, 10, 14, 18 ] [ Designated as safety issue: No ]
Cognitive Function Neuropsychological Battery (Gur Battery) [ Time Frame: Baseline, Week 18 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Structural MRI (changes in grey matter deficits), fMRI (brain oxygenation level dependent, BOLD, responses) [ Time Frame: Baseline, Week 18 ] [ Designated as safety issue: No ]

Estimated Enrollment:	150
Study Start Date:	June 2007
Estimated Study Completion Date:	February 2010
Estimated Primary Completion Date:	January 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Active Comparator	Drug: Valacyclovir + Antipsychotic 1 g PO BID x 4 weeks after 4 weeks it goes up to 1.5 g PO BID x 12 weeks
2: Placebo Comparator	Drug: Placebo + Antipsychotic 2 pills twice a day x 4 weeks, after 4 weeks 3 pills twice a day x 12 weeks

Detailed Description:

The main objective of the study is to evaluate the efficacy of add-on treatment of Valacyclovir (VAV), an antiviral medication, in the treatment of early course schizophrenia/schizoaffective disorder patients. Our main hypothesis is that the VAV add-on treatment will improve positive, negative and cognitive symptoms in herpes simplex virus (HSV) positive schizophrenia or schizoaffective disorder patients. We hypothesize that the grey matter reductions in specific brain regions (such as prefrontal regions) will improve in patients on VAV + antipsychotic compared to those on placebo + antipsychotic and the improvements in positive, negative and cognitive symptoms will be correlated with the grey matter changes.

Eligibility

Ages Eligible for Study:	18 Years to 50 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Both genders between the ages of 18-50 years
Schizophrenia or schizoaffective disorder as defined in DSM-IV
Duration of illness 10 years or less
On a stable dose of an antipsychotic medication for at least a month
Should score 4 or more on at least one of the subscales of PANSS
Positive for HSV1
Written informed consent

Exclusion Criteria:

Substance abuse in the last month/dependence 6 months prior to the study
History of, or current medical/neurological illnesses which affects CNS function e.g., epilepsy, head injury with prolonged loss of consciousness
Pregnancy
History of immune disorders, HIV infection or currently receiving immunosuppressants
Subjects on regular antiviral therapy
History of hypersensitivity to Valacyclovir
Mental retardation as defined in DSM-IV

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00514449

Contacts

Contact: Alicia Thomas, BA	1-866-461-3219	thomasaa@upmc.edu
Contact: Debra M. Montrose, PhD, LSW	412-586-9020	montrosedm@upmc.edu

Locations

United States, Michigan
Wayne State University	Recruiting
Detroit, Michigan, United States, 48201
Contact: Myung Mae Nordin mnordin@med.wayne.edu
Sub-Investigator: Matcheri Keshavan, MD
United States, Pennsylvania
Western Psychiatric Institute and Clinic	Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: Alicia Thomas, BA 412-586-9096 thomasaa@upmc.edu
Principal Investigator: Konasale Prasad, MD

Sponsors and Collaborators

University of Pittsburgh

Stanley Medical Research Institute

Wayne State University

Investigators

Principal Investigator:

Konasale Prasad, MD

Western Psychiatric Institute and Clinic

More Information

Publications:

Prasad KM, Shirts BH, Yolken RH, Keshavan MS, Nimgaonkar VL. Brain morphological changes associated with exposure to HSV1 in first-episode schizophrenia. Mol Psychiatry. 2007 Jan;12(1):105-13, 1. Epub 2006 Oct 10.

Responsible Party:	Western Psychiatric Instititute and Clinic ( Konasale Prasad, MD )
Study ID Numbers:	0602032
Study First Received:	August 8, 2007
Last Updated:	July 6, 2009
ClinicalTrials.gov Identifier:	NCT00514449 History of Changes
Health Authority:	United States: Institutional Review Board

Study placed in the following topic categories:

Valacyclovir
Schizophrenia
Anti-Infective Agents
Tranquilizing Agents
Mental Disorders
Psychotropic Drugs

Central Nervous System Depressants
Psychotic Disorders
Antipsychotic Agents
Antiviral Agents
Schizophrenia and Disorders with Psychotic Features

Additional relevant MeSH terms:

Anti-Infective Agents
Tranquilizing Agents
Physiological Effects of Drugs
Psychotropic Drugs
Central Nervous System Depressants
Antipsychotic Agents
Antiviral Agents
Pharmacologic Actions

Schizophrenia
Valacyclovir
Mental Disorders
Therapeutic Uses
Psychotic Disorders
Central Nervous System Agents
Schizophrenia and Disorders with Psychotic Features

ClinicalTrials.gov processed this record on September 04, 2009